Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 in Recurrent Endometrial Cancer
NCT00087685Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2004
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in endometrial cancer (EC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Objective Response Plus Stable Disease Rate (CR + PR + SD) at 8 weeks and Clinical Benefit Rate at 20 weeks. Started Jun 2004; status: completed.
02
Drugs
everolimus
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00087685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087685.